Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection: A Subgroup Analysis of a Randomized Phase-III Multicenter Study.
Angele, Martin K. MD *; Albertsmeier, Markus MD *; Prix, Niclas J. MD *; Hohenberger, Peter MD ++; Abdel-Rahman, Sultan MS +; Dieterle, Nelli +; Schmidt, Michael MD [S]; Mansmann, Ulrich [S]; Bruns, Christiane J. MD [P]; Issels, Rolf D. MD +; Jauch, Karl-Walter MD *; Lindner, Lars H. MD +
Annals of Surgery.
260(5):749-756, November 2014.
(Format: HTML, PDF)
Objective: To determine whether regional hyperthermia (RHT) in addition to chemotherapy improves local tumor control after macroscopically complete resection of abdominal or retroperitoneal high-risk sarcomas.
Background: Within the prospectively randomized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progression-free survival (LPFS) and disease-free survival (DFS) in patients with abdominal and extremity sarcomas. That trial included macroscopically complete and R2 resections.
Methods: A subgroup analysis of the EORTC trial was performed and long-term survival determined. From 341 patients, 149 (median age 52 years, 18-69) were identified with macroscopic complete resection (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10 cm, G2 48.3%, G3 51.7%). Seventy-six patients were treated with EIA (etoposide, ifosfamide, doxorubicin) RHT (>=5 cycles: 69.7%) versus 73 patients receiving EIA alone (>=5 cycles: 52.1%, P = 0.027). LPFS and DFS as well as overall survival were determined.
Results: RHT and systemic chemotherapy significantly improved LPFS (56% vs 45% after 5 years, P = 0.044) and DFS (34% vs 27% after 5 years, P = 0.040). Overall survival was not significantly improved in the RHT group (57% vs 55% after 5 years, P = 0.82). Perioperative morbidity and mortality were not significantly different between groups.
Conclusions: In patients with macroscopically complete tumor resection, RHT in addition to chemotherapy resulted in significantly improved local tumor control and DFS without increasing surgical complications. Within a multimodal therapeutic concept for abdominal and retroperitoneal high-risk sarcomas, RHT is a treatment option beside radical surgery and should be further evaluated in future trials.
(C) 2014 by Lippincott Williams & Wilkins.